Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03818672 · ClinicalTrials.gov registry record · Phase 4
Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects
A Phase 4 study, sponsored by Bausch Health Americas.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT03818672 is a Phase 4 study that was terminated before completion, run by Bausch Health Americas. The registered enrollment target is 5 participants.
The verdict
NCT03818672, a Phase 4 study, was terminated before completion, sponsored by Bausch Health Americas.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary objective of this study is to characterize the steady state plasma
Interventions
- DRUG Rifaximin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-01-29 |
| Est. Completion | 2020-02-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03818672
The ClinicalTrials.gov registry entry for NCT03818672 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rifaximin is the first listed.
NCT03818672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03818672 about?
NCT03818672 is a clinical study titled "Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects". The primary objective of this study is to characterize the steady state plasma
What is the current status of trial NCT03818672?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2019-01-29. Estimated completion is 2020-02-02.
What interventions are being tested in trial NCT03818672?
The interventions under investigation include: Rifaximin (DRUG).
Who is sponsoring clinical trial NCT03818672?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.